Quick Answer
BioRestorative Therapies, Inc. reported Revenue (ASC 606) of $359.7 thousand for fiscal year 2025.
BioRestorative Therapies, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $359.7K | -10.3% |
| 2024 | $401.0K | +175.0% |
| 2023 | $145.8K | +21.7% |
| 2022 | $119.8K | +160.4% |
| 2021 | $46.0K | -40.3% |
| 2020 | $77.0K | -40.8% |
| 2019 | $130.0K | +17.1% |
| 2018 | $111.0K | +37.0% |
| 2017 | $81.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.8K | -94.9% | -96.1% |
| June 30, 2025 | $303.3K | +240.4% | +1113.2% |
| March 31, 2025 | $25.0K | -28.6% | -89.3% |
| September 30, 2024 | $233.6K | +660.9% | +162.2% |
| June 30, 2024 | $89.1K | +38.1% | +154.6% |
| March 31, 2024 | $35.0K | +11.8% | +14.0% |
| September 30, 2023 | $30.7K | +5.9% | -52.4% |
| June 30, 2023 | $64.5K | -9.3% | +106.1% |
- BioRestorative Therapies, Inc. showed a decrease of -10.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, BioRestorative Therapies, Inc.’s revenue (asc 606) has grown by 344.1% (from $81.0 thousand to $359.7 thousand).
- The most recent figure is from BioRestorative Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: